Exact Sciences Is Maintained at Outperform by Evercore ISI Group
Exact Sciences Is Maintained at Outperform by Evercore ISI Group
Evercore ISI Group Maintains Outperform on Exact Sciences, Lowers Price Target to $72
Evercore ISI Group analyst Vijay Kumar maintains Exact Sciences (NASDAQ:EXAS) with a Outperform and lowers the price target from $80 to $72.
Exact Sciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/02/2024 67.42% Evercore ISI Group $80 → $72 Maintains Outperform 06/27/2024 62.77% BTIG $80 → $70 Maint
Evercore Maintains Exact Sciences(EXAS.US) With Buy Rating, Cuts Target Price to $72
Evercore analyst Vijay Kumar maintains $Exact Sciences(EXAS.US)$ with a buy rating, and adjusts the target price from $90 to $72.According to TipRanks data, the analyst has a success rate of 47.4% and
Express News | Geneoscopy: Confident Litigation Will Not Delay Commercial Launch of Colosense
Express News | Geneoscopy: Files Counterclaims Against Exact Sciences
Exact Sciences Initiated at Sector Outperform at Scotiabank on Advanced Diagnostics
Exact Sciences Initiated at Sector Outperform by Scotiabank
Exact Sciences Initiated at Sector Outperform by Scotiabank
Jefferies Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $75
Jefferies analyst Tycho Peterson maintains $Exact Sciences(EXAS.US)$ with a buy rating, and maintains the target price at $75.According to TipRanks data, the analyst has a success rate of 55.3% and a
Scotiabank Initiates Exact Sciences at Sector Outperform With $70 Price Target
Exact Sciences (EXAS) has an average investment rating of buy among analysts polled by Capital IQ, with price targets ranging from $66 to $100. Price: 44.00, Change: -0.16, Percent Change: -0.36
Express News | Exact Sciences Corp : Btig Cuts Target Price to $70 From $80
Express News | Exact Sciences Corp : Scotiabank Initiates Coverage With Sector Outperform Rating; Target Price $70
Scotiabank Initiates Exact Sciences(EXAS.US) With Buy Rating, Announces Target Price $70
Scotiabank analyst Sung Ji Nam initiates coverage on $Exact Sciences(EXAS.US)$ with a buy rating, and sets the target price at $70.According to TipRanks data, the analyst has a success rate of 45.0% a
Exact Sciences Gains as TD Cowen Sees 25% Price Hike for Next-gen Cologuard
Expert Outlook: Exact Sciences Through The Eyes Of 5 Analysts
5 analysts have expressed a variety of opinions on Exact Sciences (NASDAQ:EXAS) over the past quarter, offering a diverse set of opinions from bullish to bearish.Summarizing their recent assessments,
BTIG Maintains Exact Sciences(EXAS.US) With Buy Rating, Cuts Target Price to $70
BTIG analyst Mark Massaro maintains $Exact Sciences(EXAS.US)$ with a buy rating, and adjusts the target price from $80 to $70.According to TipRanks data, the analyst has a success rate of 29.8% and a
NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Citigroup r
Exact Sciences Is Maintained at Buy by BTIG
Exact Sciences Is Maintained at Buy by BTIG
Exact Sciences Price Target Cut to $70.00/Share From $80.00 by BTIG
Exact Sciences Price Target Cut to $70.00/Share From $80.00 by BTIG
BTIG Maintains Buy on Exact Sciences, Lowers Price Target to $70
BTIG analyst Mark Massaro maintains Exact Sciences (NASDAQ:EXAS) with a Buy and lowers the price target from $80 to $70.